| Revenue growth | 32% YoY FY26; 35% 2YR CAGR. |
|---|---|
| Margins | EBITDA margin increased from 11.0% in FY24 to 20.4% in FY26. |
| Demand visibility | Strong domestic demand; exports emerging as next growth lever. |
| Management confidence | High, citing four decades of expertise and scalable infrastructure. |
Growth
Revenue grew at 35% 2YR CAGR; EBITDA margin expanded 940 bps to 20.4% over 2 years.
Outlook
Targeting 14.21% Home & Personal Care contribution by Sept 2025; expanding capacity to 22,000 MTPA.
Risks
Single-segment concentration in textiles; high debtor days (122) and inventory days (127) impact cash cycles.
Earnings Call filed with NSE, NSE: NEOCHEM. Summary written with AI assistance from the document.
Neochem Bio Solutions Ltd: key numbers
- Share price
- ₹106.20
- Market cap
- ₹181.8 Cr
- Revenue (annual)
- ₹110.7 Cr
- Net profit (annual)
- ₹12.03 Cr
- P/E (TTM)
- 15.1×Sector 37.5×
- Promoter holding
- 66.72%
- FII holding
- 0.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neochem Bio Solutions Ltd
All →Neochem Bio Solutions Annual General Meeting
Neochem Bio Solutions Limited held its 9th Annual General Meeting on September 21, 2026, where management reviewed the company's performance and discussed future business strategies.
Neochem Bio Solutions Promoter Buying: ₹0.14 Cr
Promoter Swapnil R. Makati acquired 1,200 equity shares of Neochem Bio Solutions Limited for ₹0.14 Crore via an on-market purchase.
- Value
- ₹0.14 Cr
- Promoter stake change
- +0.01%
Neochem Bio Solutions Promoter Buying: ₹0.07 Cr
Promoter and MD Swapnil Makati purchased 7,200 Neochem Bio Solutions shares on NSE for ₹0.07 Crore. His stake rose from 54.70% to 54.74%.
- Value
- ₹0.07 Cr
- Promoter stake change
- +0.04%
Neochem Bio Solutions Earnings Call: Key Takeaways
Neochem Bio Solutions delivered strong FY26 results with 32% revenue growth and 53% EBITDA growth, driven by a shift to own-brand performance chemicals and expansion into HPC and paints.
Neochem Bio Solutions Earnings Call: Key Takeaways
Neochem Bio Solutions delivered a strong FY26 with 32% revenue growth and 53% EBITDA expansion, driven by a strategic pivot from white-label manufacturing to its own higher-margin specialty brand.
Neochem Bio Solutions Earnings Call: Key Takeaways
Neochem Bio Solutions Limited reported FY26 Total Income of ₹113.4cr, reflecting 32% YoY growth. Strategy focuses on diversifying from textile into HPC and industrial specialty chemicals.